Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-HYNIC-exendin-4
- Development stage
- Unknown
- Lead developer
- Jagiellonian University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
99mTc-HYNIC-exendin-4 (also known as [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4) is an investigational radiodiagnostic peptide tracer used for single-photon emission computed tomography (SPECT) or SPECT/CT imaging of the glucagon-like peptide-1 (GLP-1) receptor. The tracer consists of exendin-4, a GLP-1 receptor agonist peptide that is resistant to dipeptidyl peptidase IV (DPP-4) degradation, conjugated to a hydrazinonicotinamide (HYNIC) chelator via an aminohexanoic acid (Ahx) spacer at a lysine-40 residue, and radiolabeled with technetium-99m (99mTc) using ethylenediaminediacetic acid (EDDA) as a co-ligand. It is primarily developed for the preoperative localization of occult insulinomas (insulin-secreting pancreatic neuroendocrine tumors) and other conditions associated with endogenous hyperinsulinemic hypoglycemia (EHH), such as nesidioblastosis, particularly in patients where conventional imaging modalities (CT, MRI, ultrasound) are negative or inconclusive.
- Other names
- [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-499mTc-HYNIC-Ahx-Lys40-exendin-499mTc-hydrazinonicotinamide-aminohexanoic acid-Lys40-exendin-4technetium-99m-HYNIC-exendin-4technetium99m-HYNIC-exendin-4technetium 99m-HYNIC-exendin-4
02
Targets
Beyond the preview
Go deeper on 99mTc-HYNIC-exendin-4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-HYNIC-exendin-4.